Login
Powered by
MOMENTUM
MEDIA
Powered by MOMENTUM MEDIA
Norton Rose Fulbright has advised Nature’s Care on a trade sale, in one of the largest private equity investments in Australia so far in 2018.
Firm: Norton Rose Fulbright (Nature’s Care), Deutsche Bank, Clifford Chance and PricewaterhouseCoopers (buyer’s consortium, comprising China Jianyin Investment [JIC] and Tamar Alliance Partners Fund [Tamar]).
The deal is expected to close later in 2018, subject to regulatory approvals in China, Europe and the Foreign Investment Review Board in Australia.
Value: Undisclosed
Area: Private equity
Key players: The cross-border team was led by NRF partner and head of private equity Richard G. Lewis, who was supported by special counsel Matthew Nelson, associate William Nicolson, and lawyers Andrew Robertson and Hugo Gotterson.
The team also received specialist support from lawyers in the NRF Sydney, London and Shanghai offices.
Deal significance: While the Wu family is selling its majority share in the business, it will continue to hold an undisclosed interest in the business it built.
Speaking about the deal, Mr Lewis said the firm had been tracking rising interest from Chinese businesses in Australian life sciences and healthcare industries, which are part of NRF’s major areas of focus.
“The sale of Nature’s Care is illustrative of the appetite for Chinese investment in high-quality Australian healthcare businesses,” Mr Lewis said.
“We’re pleased to have been able to bring together a high-quality cross-border team to assist the Wu family in this significant transaction.”
Jerome Doraisamy is the managing editor of Lawyers Weekly and HR Leader. He is also the author of The Wellness Doctrines book series, an admitted solicitor in New South Wales, and a board director of the Minds Count Foundation.
You can email Jerome at:
Get breaking news
Jerome Doraisamy
